Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$138.58M
Enterprise ValueAU$91.72M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding923,874,150
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$21.39M
Bulls Say, Bears Say
Bulls Say
Material U.S. Distribution AgreementA six‑year exclusive PHASE distribution contract with a USD 317M minimum provides multi‑year, contractually backed revenue visibility. That guaranteed demand supports capacity planning, de‑risks U.S. commercialization execution and strengthens cashflow predictability if fulfilled.
Reimbursement SecuredEstablished Medicare/MAC reimbursement at USD 41.38 per test creates a durable payment pathway for physician offices and clinics. Stable reimbursement reduces adoption friction, improves per‑test economics, and supports sustained demand growth in decentralized care settings over multiple years.
High Product Gross MarginsConsistently high gross margins (≈68% company, >60% for FebriDx) indicate attractive unit economics. These margins provide room to absorb commercial and R&D investment, improving the prospect of sustainable profitability as product volumes scale and fixed costs are leveraged over time.
Bears Say
High Leverage And Weak Equity ReturnsA debt/equity ratio above 1 and negative return on equity point to a leveraged capital structure and poor capital efficiency. High leverage constrains financial flexibility, raises interest and refinancing risk, and limits the company's ability to fund required investments without external financing.
Persistent Cash Flow WeaknessHistoric negative operating and free cash flows signal limited internal cash generation. Although H1 showed improvement, ongoing negative cash flow dynamics increase reliance on external financing and grants, complicating sustained investment in manufacturing scale and U.S. commercial rollout.
Dependence On CLIA WaiverKey commercial expansion and activation of the PHASE agreement depend on a CLIA waiver from the FDA. This regulatory dependency is a structural execution risk: without waiver approval the addressable in‑office market and the majority of projected volume remain constrained.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.02 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$138.58M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 106 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 923,874,150 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:LDX Sentiment 94%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$119.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-164.12%
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---